CE7A3262-C48A-43BF-941C-9D2482B9CACD
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.088042049934297
- age_years
- 85
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.582
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.574
- ANGIOGENESIS+0.499
- G2M_CHECKPOINT+0.499
- E2F_TARGETS+0.494
- INTERFERON_GAMMA_RESPONSE+0.486
- TNFA_SIGNALING_VIA_NFKB+0.481
- DNA_REPAIR+0.480
- MTORC1_SIGNALING+0.478
- IL6_JAK_STAT3_SIGNALING+0.468
Top 10 suppressed
- KRAS_SIGNALING_DN-0.421
- SPERMATOGENESIS-0.252
- MYOGENESIS-0.143
- PANCREAS_BETA_CELLS-0.125
- BILE_ACID_METABOLISM+0.000
- WNT_BETA_CATENIN_SIGNALING+0.049
- HEME_METABOLISM+0.064
- APICAL_SURFACE+0.067
- MITOTIC_SPINDLE+0.102
- ESTROGEN_RESPONSE_EARLY+0.126
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.990 |
| 2 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.985 |
| 3 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.984 |
| 4 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.981 |
| 5 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.979 |
| 6 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.978 |
| 7 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.978 |
| 8 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.977 |
| 9 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.976 |
| 10 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.975 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.582 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.574 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.499 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.499 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.494 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.486 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.481 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.480 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.478 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.468 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.466 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.460 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.457 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.455 | Inavolisib | — uncovered |
| APOPTOSIS | 0.454 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.449 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.448 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.445 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.438 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.419 | Inavolisib | — uncovered |